Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast...Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining <sup>18</sup>F-FES with ER, <sup>18</sup>F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method <sup>18</sup>F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging <sup>18</sup>F-FDG PET/CT in breast cancer.展开更多
Background: Neoadjuvant chemoradiotherapy (CRT) is frequently performed for esophageal squamous cell carcinoma. In this study, we retrospectively assessed the standardized uptake value (SUV) of FDG-PET against decreas...Background: Neoadjuvant chemoradiotherapy (CRT) is frequently performed for esophageal squamous cell carcinoma. In this study, we retrospectively assessed the standardized uptake value (SUV) of FDG-PET against decreased rates of SUV to assess the response of advanced esophageal squamous cell carcinoma patients to neoadjuvant CRT, and the correlation of this response with histopathological findings. Patients and Methods: Thirty-three patients receiving CRT followed by surgery were analyzed. Results: Using the decreased rate of maximum SUV, the sensitivity and specificity in distinguishing complete responders (CR) from non-CR patients was 63% and 44%. Using the maximum SUV before surgery, the sensitivity and specificity for distinguishing pathological CR from non-CR was 88% and 56%. Conclusions: To identify complete responders of CRT for esophageal cancer, absolute maximum SUV value is a better predictor than decreased rate of the maximum SUV.展开更多
目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术...目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术前1周内进行了18F-F DG P ET/CT显像检查,并在术后3~6个月内进行了复查,监测复发或转移情况。术前的TNM分期和术后的复发转移情况均以手术病理结果或临床随访结果为金标准进行评估。结果术前分期诊断中,18F-FD(G P ET/CT显像的T分期、N分期和M分期的符合率分别为86.59%、81.93%和100%,一致性检验Kappa值分别为0.834、0.793和1.000。术后的复发转移检测中,18F-FDG PET/CT显像在术后6个月内成功检出了22例(88.00%)的复发转移病例,其诊断灵敏度为88.00%,特异度为100.00%。结论18F-FDG PET/CT显像在肺癌术前分期以及术后复发转移的预测中具有较高的准确性和可靠性,该方法可以为临床提供有效的参考信息,有助于医生制定更准确的治疗方案和更有效的随访策略。展开更多
Objective: We evaluated whether the changes in FDG-PET/CT uptake between pre/and post-treatment might predict a complete response in esophageal cancer (EC). Patients and Methods: Fifty-six patients with 2 PET-CTs stud...Objective: We evaluated whether the changes in FDG-PET/CT uptake between pre/and post-treatment might predict a complete response in esophageal cancer (EC). Patients and Methods: Fifty-six patients with 2 PET-CTs studies were evaluated retrospectively. Images were evaluated qualitatively and semiquantitatively (SUVs). Patients were classified as persistence of disease, complete metabolic response and unspecific FDG uptake. The SUVmax values and percentages of change in SUV were measured. Results: A significant difference was found between the persistence group and the non-persistence group regarding the median percentage change in SUVtumor (72.95% vs. 54.12%;p = 0.04) and regarding the percentage change in SUVnode (89.91% vs. 59.91%, p = 0.04). In patients treated with radiochemotherapy (RCTX), a significant difference was found between the persistence group and the no persistence group regarding the percentage change in SUVtumor (58.02% vs. 78.59%). Overall survival rate was related to the percentage of change in the SUVtumor. The group of ≥75% of change SUVtumor showed a median survival of 37.32 months (IC: 95% = 49.93 - 24.70) and the group of <75% of change SUVtumor showed a median survival of 18.39 months (IC: 95% = 25.14 - 11.65) (p = 0.04). In patients with metastatic relapse, a significant difference was found regarding the percentage change in SUVnode (94.63% vs. 74.09%). Conclusion: Our study provides evidence that the percentage change in the SUVmax is a predictor of the response to neoadjuvant treatment in patients with EC. When SUVmax decreases by 72.95% or more, the patient is likely a complete responder.展开更多
文摘Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining <sup>18</sup>F-FES with ER, <sup>18</sup>F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method <sup>18</sup>F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging <sup>18</sup>F-FDG PET/CT in breast cancer.
文摘Background: Neoadjuvant chemoradiotherapy (CRT) is frequently performed for esophageal squamous cell carcinoma. In this study, we retrospectively assessed the standardized uptake value (SUV) of FDG-PET against decreased rates of SUV to assess the response of advanced esophageal squamous cell carcinoma patients to neoadjuvant CRT, and the correlation of this response with histopathological findings. Patients and Methods: Thirty-three patients receiving CRT followed by surgery were analyzed. Results: Using the decreased rate of maximum SUV, the sensitivity and specificity in distinguishing complete responders (CR) from non-CR patients was 63% and 44%. Using the maximum SUV before surgery, the sensitivity and specificity for distinguishing pathological CR from non-CR was 88% and 56%. Conclusions: To identify complete responders of CRT for esophageal cancer, absolute maximum SUV value is a better predictor than decreased rate of the maximum SUV.
文摘目的分析放射性荧光脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)显像在肺癌术前分期诊断及复发转移预测中的应用价值。方法 回顾性分析2022年9月至2023年6月期间80例初诊肺癌患者的临床和影像学数据,所有患者均在术前1周内进行了18F-F DG P ET/CT显像检查,并在术后3~6个月内进行了复查,监测复发或转移情况。术前的TNM分期和术后的复发转移情况均以手术病理结果或临床随访结果为金标准进行评估。结果术前分期诊断中,18F-FD(G P ET/CT显像的T分期、N分期和M分期的符合率分别为86.59%、81.93%和100%,一致性检验Kappa值分别为0.834、0.793和1.000。术后的复发转移检测中,18F-FDG PET/CT显像在术后6个月内成功检出了22例(88.00%)的复发转移病例,其诊断灵敏度为88.00%,特异度为100.00%。结论18F-FDG PET/CT显像在肺癌术前分期以及术后复发转移的预测中具有较高的准确性和可靠性,该方法可以为临床提供有效的参考信息,有助于医生制定更准确的治疗方案和更有效的随访策略。
文摘Objective: We evaluated whether the changes in FDG-PET/CT uptake between pre/and post-treatment might predict a complete response in esophageal cancer (EC). Patients and Methods: Fifty-six patients with 2 PET-CTs studies were evaluated retrospectively. Images were evaluated qualitatively and semiquantitatively (SUVs). Patients were classified as persistence of disease, complete metabolic response and unspecific FDG uptake. The SUVmax values and percentages of change in SUV were measured. Results: A significant difference was found between the persistence group and the non-persistence group regarding the median percentage change in SUVtumor (72.95% vs. 54.12%;p = 0.04) and regarding the percentage change in SUVnode (89.91% vs. 59.91%, p = 0.04). In patients treated with radiochemotherapy (RCTX), a significant difference was found between the persistence group and the no persistence group regarding the percentage change in SUVtumor (58.02% vs. 78.59%). Overall survival rate was related to the percentage of change in the SUVtumor. The group of ≥75% of change SUVtumor showed a median survival of 37.32 months (IC: 95% = 49.93 - 24.70) and the group of <75% of change SUVtumor showed a median survival of 18.39 months (IC: 95% = 25.14 - 11.65) (p = 0.04). In patients with metastatic relapse, a significant difference was found regarding the percentage change in SUVnode (94.63% vs. 74.09%). Conclusion: Our study provides evidence that the percentage change in the SUVmax is a predictor of the response to neoadjuvant treatment in patients with EC. When SUVmax decreases by 72.95% or more, the patient is likely a complete responder.
